The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jun. 26, 2012

Filed:

Dec. 17, 2004
Applicants:

Wilfried Braje, Rinteln, DE;

Andreas Haupt, Schwetzingen, DE;

Wilfried Lubisch, Heidelberg, DE;

Roland Grandel, Dossenheim, DE;

Karla Drescher, Dossenheim, DE;

Herve Geneste, Neuhofen, DE;

Liliane Unger, Ludwigshafen, DE;

Daryl R. Sauer, Trevor, WI (US);

Inventors:

Wilfried Braje, Rinteln, DE;

Andreas Haupt, Schwetzingen, DE;

Wilfried Lubisch, Heidelberg, DE;

Roland Grandel, Dossenheim, DE;

Karla Drescher, Dossenheim, DE;

Herve Geneste, Neuhofen, DE;

Liliane Unger, Ludwigshafen, DE;

Daryl R. Sauer, Trevor, WI (US);

Assignee:

Abbott GmbH & Co. KG, Wiesbaden, DE;

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61P 25/00 (2006.01); A61K 31/55 (2006.01); C07D 223/16 (2006.01); C07D 409/12 (2006.01);
U.S. Cl.
CPC ...
Abstract

The invention relates to tetrahydrobenzazepines of the general formula I in which the variables Ar, A, B, Y, Rand Rhave the meanings indicated in claim, as well as the N-oxides of these compounds, the physiologically tolerated acid addition salts of these compounds and the physiologically tolerated acid addition salts of the N-oxides. The invention also relates to a pharmaceutical composition that comprises at least one tetrahydrobenzazepine compound of the formula I, the physically tolerated acid addition salt of I, the N-oxide of compound of the formula I and/or the physically tolerated acid addition salts of the N-oxides of I, and further to the use of a compound according to the present invention for treating disorders that respond beneficially to dopamine Dreceptor antagonists or dopamine Dagonists. The compounds according to the invention are preferably useful for the treatment of disorders of the central nervous system such as schizophrenia and depression and for the treatment of renal function disorders.


Find Patent Forward Citations

Loading…